Substantial Weight Loss Achieved with Hansoh's Olatorepatide in Phase III Clinical Trial at EASD

Significant Weight Loss Results from the EASD 2026 Conference

From September 28 to October 2, 2026, the Annual Meeting of the European Association for the Study of Diabetes (EASD) took place in Milan, showcasing cutting-edge research in diabetes management. A standout presentation was from Hansoh Pharma regarding their innovative drug Olatorepatide, a dual-biased GLP-1/GIP receptor agonist. This medication was evaluated in a Phase III randomized, double-blind, placebo-controlled study called LIGHTEN, focusing on weight management among overweight and obese adults in China.

Clinical Trial Overview

The LIGHTEN study enrolled 604 adult participants, each with a BMI of 28 kg/m² or higher, or a BMI of 24–28 kg/m² alongside a weight-related comorbidity. Participants were divided among four groups, receiving subcutaneous injections of Olatorepatide in doses of 5 mg, 10 mg, or 15 mg once weekly, while a placebo group received no active drug. After a treatment period of 48 weeks, the primary endpoints assessed were the percentage change in body weight and the proportion of participants achieving significant weight loss (≥5%).

Exceptional Weight Loss Results

The findings from the study revealed impressive results. Participants who were administered 15 mg of Olatorepatide achieved an average weight loss of 19.3% at Week 48, with no evidence of a weight-loss plateau. Weight loss rates among the various dosages were as follows: 12.5% for 5 mg, 17.5% for 10 mg, and 19.3% for 15 mg, contrasted with just a 2.7% reduction in the placebo group, demonstrating statistically significant differences (P < 0.0001). Furthermore, waist circumference in the 15 mg group also decreased significantly, averaging a reduction of 16.0 cm.

Gastrointestinal Tolerability and Safety Profile

Noteworthy was the favorable gastrointestinal tolerability of Olatorepatide when compared to existing therapies. The study reported a low occurrence of nausea (7.8%) and vomiting (4.9%), significantly below historical rates associated with similar obesity treatments. Additionally, adverse events unrelated to the treatment, such as diarrhea and constipation, were also within acceptable ranges, indicating a robust safety profile that can potentially ensure higher patient compliance.

Metabolic Benefits

Beyond weight loss, Olatorepatide demonstrated improvements in critical metabolic markers, including blood pressure, lipid levels, and glycated hemoglobin (HbA1c). These results suggest that Olatorepatide may not only aid in weight management but also enhance overall metabolic health—a crucial consideration in treating obesity.

Global Recognition at EASD

The recognition of this Phase III study as a Late-breaking Abstract (LBA) oral presentation speaks volumes of its international impact and relevance. The selection showcases the confidence in the quality of the data and its implications for future treatments in diabetes and obesity management.

Future Implications

Olatorepatide is also undergoing further clinical trials for the treatment of type 2 diabetes mellitus. With ongoing development, including an NDA (New Drug Application) submitted to the National Medical Products Administration (NMPA) in China targeting long-term weight management, Hansoh Pharma is positioning itself as a leader in transformative diabetes treatment solutions.

As the need for effective weight management solutions continues to rise globally, innovations like Olatorepatide may define future standards for obesity treatment, enhancing both patient outcomes and quality of life.

In essence, the clinical results from the EASD 2026 conference herald an exciting advancement in pharmacotherapy for individuals struggling with obesity, marking a promising horizon for Hansoh Pharma's ongoing mission to innovate healthcare solutions.